News

Denosumab Update Shows 5-Month Advantage in Advanced Breast Cancer

Publish date: December 13, 2010

 

FROM THE SAN ANTONIO BREAST CANCER SYMPOSIUM

Dr. Stopeck disclosed that she serves as a consultant to and has received research grants from both Amgen, which markets denosumab, and Novartis, which markets zoledronic acid. The trial was sponsored by Amgen in collaboration with Daiichi Sankyo.

Pages

Recommended Reading

Outcomes of Acute Kidney Injury in Cancer Patients Studied
MDedge Internal Medicine
Frail Elderly Benefit From Post-Op Temozolomide for Glioblastoma
MDedge Internal Medicine
Even One Cigarette Is Harmful, Surgeon General's Report Finds
MDedge Internal Medicine
BEACOPP Plus ABVD Called 'New Standard' for Hodgkin's Lymphoma
MDedge Internal Medicine
Zoledronic Acid Sinks as Breast Cancer Therapy in AZURE Trial
MDedge Internal Medicine
Obesity Linked to Worse Outcomes in Common Breast Cancer Subtype
MDedge Internal Medicine
Double Cord Blood Transplant Better Than Single in Acute Leukemia
MDedge Internal Medicine
Trastuzumab/Pertuzumab Doublet Eradicates Some Early Breast Cancer
MDedge Internal Medicine
Bevacizumab Short of Mark in First Neoadjuvant Breast Cancer Trial
MDedge Internal Medicine
Ara-C Prolongs Time to Treatment Failure in Mantle Cell Lymphoma
MDedge Internal Medicine